Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical teratoid rhabdoid tumors. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group; as well as licence agreement with Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.…
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026
Kazia Therapeutics (NASDAQ: KZIA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 4.920 USD on 20 November 2026, down 35.3% over 52 weeks. Its 52-week range is 4.500 USD to 17.40 USD: the price is 71.7% below the high and 9.3% above the low.
Its market capitalisation is 76.50M USD.
Kazia Therapeutics reports return on equity of 249.4% and revenue down 3.5% year over year.
It holds more cash than debt, a net cash position of 61.19M AUD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.